"CLL – diagnosis, management, treatment and outcome in the new era with kinase inhibitors"
Dr Francesco Forconi MD, DM, PhD, FRCPath Associate Professor in Haematological Oncology, Honorary Consultant in Haematology stresses the importance of Patients in helping the research team at Southampton to development improvements to treatments and to the quality of life for patients.

His talk starts with an overview: Diagnosis of CLL. why so many are on watch and wait, What is CLL? How CLL is diagnosed. How diagnostic tools have improved and the identification of prognostic and predictive characteristics became possible. How the origin of a CLL and the characteristics of the immunoglobulin genes are significant as prognostic and predictive information that aid in understanding potential different clinical courses.

Dr Forconi goes on to explain the significance of immunoglobulin expression on the surface of a CLL cell, among other tests.

Fitness of a patient has historically determined the treatment that a patient can tolerate . The new treatments like ibrutinib and venetoclax are now in use by patients unable to tolerate, who fail or are unsuitable for treatment of toxic therapies These are proving to further improve survival. Patients are now providing data that can potentially further improve how CLL is treated into the future. The ongoing research into this data and use of these drugs by many at Southampton and around the globe will continue to generate improvements into the quality of life and survival of patients with CLL.


.

свернуть